Sugi Predict

Sugi Predict / Compounds / SCHEMBL142967

SCHEMBL142967

SCHEMBL142967

COC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 2/20 0.40
▸ UCHL1 P09936 1/20 0.38
▸ NR1H2 P55055 2/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ MMP2 P08253 3/20 0.37
▸ ANPEP P15144 3/20 0.37
▸ PTPN1 P18031 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CCR2 P41597 1/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ CHRM3 P20309 1/20 0.32
▸ HTRA1 Q92743 1/20 0.32
▸ PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7456999 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL6624196 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL18577311 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL1269514 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL2387781 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL24826391 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL1269513 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL29548437 0.92 UCHL1 (0.37) P2RX3UCHL1NR1H2CYP1A2POLB
SCHEMBL28567716 0.90 P2RX3 (0.41) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL24998822 0.90 P2RX3 (0.41) P2RX3UCHL1NR1H2NR1H3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 — — EP disclosed
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-05-07 — — US disclosed
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 — — EP disclosed
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 — — US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 — — EP disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
EP-4565579-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Theras, Inc. (US) 2025-06-11 — — EP disclosed
WO-2025106362-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-05-22 — — WO disclosed
EP-3841086-B1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-04-23 — — EP disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
US-5374720-A A thienamycins bactericides has nontoxic, side effect reduction against the kidney and central nervous system BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-12-20 — — US disclosed
EP-0394991-B1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO (JP) 1994-08-17 — — EP disclosed
WO-1993011128-A1 AMINOALKYLPYRROLIDINYLTHIOCARBAPENEM DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-10 — — WO disclosed
EP-0545290-A1 Aminoalkylpyrrolidinylthiocarbapenem derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-09 — — EP disclosed
EP-0272456-B1 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-03-31 — — EP disclosed
US-5102877-A Carbapenicillin antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-07 — — US disclosed
EP-0449191-A1 2-(Substituted pyrrolidinylthio)carbapenem derivatives Banyu Pharmaceutical Co., Ltd. (JP) 1991-10-02 — — EP disclosed
EP-0394991-A1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 — — EP disclosed
US-4822787-A 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-04-18 — — US disclosed
EP-0272456-A1 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 P2RX3 1584/4885UCHL1 4354/4885NR1H2 3543/4885
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE SMG1, RACK1, TIA1 P2RX3 4593/4885UCHL1 3776/4885NR1H2 3184/4885
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS P2RX3 3087/4885UCHL1 2585/4885NR1H2 1693/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A P2RX3 3490/4885UCHL1 4873/4885NR1H2 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.